Clinical Trials Sponsored by Bioven Europe

Total 4176 results

Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
BioVex Limited

Completed

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Pancreatic Cancer

United States
BioVex Limited

Completed

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Melanoma

United States, United Kingdom
Lynkcell Europe

Available

An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

Kidney Cancer | Clear Cell Kidney Cancer | Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Biogen
AbbVie

Completed

Daclizumab Japanese PK Study

Healthy

United Kingdom
Abbott
Biogen

Terminated

A Study of Volociximab in Metastatic Melanoma

Stage IV Melanoma

United States
Reata, a wholly owned subsidiary of Biogen

Terminated

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE)

Chronic Kidney Diseases | Autosomal Dominant Polycystic Kidney | Alport Syndrome

United States, France, Australia, Japan, Spain, Puerto Rico
Reata, a wholly owned subsidiary of Biogen

Completed

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

Diabetic Nephropathy

United States
Reata, a wholly owned subsidiary of Biogen

Withdrawn

A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

Type 2 Diabetes Mellitus | End-Stage Renal Disease
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 408 Capsules in Patients With Melanoma - REVEAL

Melanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) Melanoma

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Human AME Study for Omaveloxolone

Healthy Male Subjects

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers

Healthy Volunteers

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic

United States
Knopp Biosciences
Biogen

Completed

Dexpramipexole Japanese PK Study

Amyotrophic Lateral Sclerosis

United Kingdom
Biogen
Alkermes, Inc.

Completed

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Relapsing Remitting Multiple Sclerosis

United States, Germany, Poland
Genentech, Inc.
Biogen

Completed

A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis (SUNDIAL)

Rheumatoid Arthritis
Biogen
Elan Pharmaceuticals

Completed

Natalizumab Re-Initiation of Dosing

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Biogen
Elan Pharmaceuticals

Terminated

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Rheumatoid Arthritis

United States, Canada
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Withdrawn

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Crohn's Disease
BioVex Limited
Covance

Completed

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Melanoma
Biogen
Elan Pharmaceuticals

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

Pregnancy Exposure Registry for Tysabri®

Multiple Sclerosis | Pregnancy | Crohn's Disease | Prenatal Exposure

United States
Biogen
Acorda Therapeutics

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Healthy

Hong Kong, Australia
Biogen
Crescendo Biosciences

Completed

Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients (BATTER-UP)

Arthritis, Rheumatoid

United States
Biogen
Elan Pharmaceuticals

Completed

Natalizumab High Titer Immunogenicity and Safety

Multiple Sclerosis

United States
Facet Biotech
Biogen

Terminated

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Peritoneal Neoplasms | Ovarian Cancer

United States, Canada
Uni-Pharma
Biogen

Completed

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

Chronic Plaque Psoriasis
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Biosensors Europe SA

Completed

Rise Semi Compliant Balloon Study in Patient With CAD

Coronary Artery Disease

Switzerland
CytoSorbents Europe GmbH

Withdrawn

CytoSorb® in Patients With Acute on Chronic Liver Failure (HepOnFire)

Alcoholic Hepatitis | Acute on Chronic Liver Failure

Germany
Biosensors Europe SA

Active, not recruiting

Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) Study (REFORM)

Coronary Artery Disease | In-Stent Restenosis

Spain, Ireland, United Kingdom, Italy, Germany
Inspirata Europe Ltd.

Completed

Concordance Between Omnyx System With Omnyx .RTS Images and the Omnyx Dynamyx Software With Hamamatsu .NDPI Images

Diagnoses Disease

United Kingdom
Biosensors Europe SA

Unknown

BioFreedom QCA Study in CAD Patients (BioFreedomQCA)

Myocardial Infarction | Coronary Artery Disease | Cardiac Death

Spain, Denmark
Terumo Europe N.V.

Completed

e-NOBORI Observational Registry of Nobori DES (e-NOBORI)

Coronary Artery Disease

Ireland, France, Taiwan, Spain, United Kingdom, Israel, Netherlands, Czechia, Sweden, Bangladesh, Russian Federation, Brazil, Bulgaria, Serbia, Chile, Germany, Hungary, Indonesia, Georgia, Austria, Belarus, Denmark, Egypt, Estonia, Latvia, Lithuan... and more
Terumo Europe N.V.

Unknown

Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry (e-Ultimaster)

Coronary Artery Disease

Netherlands, France, United Kingdom, Austria, Ireland, Spain, Bulgaria, South Africa, Israel, Hungary, Switzerland, Chile, Belgium, Japan, Argentina, Portugal, United Arab Emirates, Serbia, Malaysia, Brazil, India, Poland, Indonesia, ... and more
Terumo Europe N.V.

Completed

Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES (DISCOVERY123)

Coronary Artery Disease

France, Netherlands, Germany
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Ciclosporin

Healthy

United Kingdom
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Montelukast

Healthy

United Kingdom
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Ritonavir

Healthy

United Kingdom
Maruho Europe Limited

Completed

Drug-Drug Interaction Study: ASP2151 and Bupropion

Healthy

United Kingdom
Biosensors Europe SA

Completed

BioFreedom FIM Clinical Trial.

Treatment Of Stenotic Lesions In Native Coronary Arteries.

Germany
Thrombotargets Europe S.L

Completed

Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction

Tooth Extraction

Spain
Kowa Research Europe

Completed

Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome (CAPITAIN)

Metabolic Syndrome

United Kingdom
Kowa Research Europe

Completed

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

Dyslipidemia | Primary Hypercholesterolemia

Spain, Denmark, India, Israel, Sweden, Finland, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, United Kingdom
Kowa Research Europe

Completed

Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin

Dyslipidemia | Hypercholesterolemia

Finland, Italy, Norway, Russian Federation, United Kingdom
Biosensors Europe SA

Recruiting

ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD

Coronary Artery Disease

United Kingdom, Germany

Clinical Trials Sponsored by Bioven Europe

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations